A Phase 3, Randomized, Observer-Blind Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's 10-Valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) Administered in a 2+1 Schedule to Healthy Infants in The Gambia
Latest Information Update: 11 May 2023
At a glance
- Drugs SIILPCV10 (Primary) ; Pneumococcal 10-valent vaccine conjugate; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 01 May 2023 Results published in The Lancet Infectious Diseases
- 21 Jul 2020 Status changed from suspended to active, no longer recruiting.
- 21 May 2020 Planned End Date changed from 1 Sep 2020 to 1 Dec 2020.